Identification and Susceptibility Profile of Vaginal Candida Species to Antifungal Agents among Pregnant Women Attending the Antenatal Clinic of Thika District Hospital, Kenya

Simple item page
dc.contributor.authorMenza, Nelson
dc.contributor.authorWanyoike, Wanjiru
dc.contributor.authorMuturi, Margaret
dc.date.accessioned2021-09-17T09:37:52Z
dc.date.available2021-09-17T09:37:52Z
dc.date.issued2013
dc.descriptionA research article published in Open Journal of Medical Microbiologyen_US
dc.description.abstractFungal infections have emerged as a world-wide health care problem in recent years, owing to the extensive use of broad-spectrum antibiotics. We screened 104 pregnant women with symptoms of vaginal candidiasis in the antenatal clinic of Thika District Hospital, Kenya in order to identify vaginal Candida species and determine their susceptibility profile to commonly used antifungal drugs for treatment of the infection. The drugs tested were fluconazole, ketoconazole, itraconazole, clotrimazole and topical nystatin. Vaginal swabs were collected and subjected to mycological and biochemical tests for Candida species identification. Susceptibility profile of the identified vaginal Candida species to the antifungal drugs was carried out using broth micro-dilution minimum inhibiting concentration method based on the approved National Committee for Clinical Laboratory Standards (NCCLS, 2002) guidelines. Candida albicans was susceptible to most of the azoles drugs while the other species had varying responses. Candida krusei and Candida glabrata species isolated were resistant to fluconazole and ketoconazole. Candida albicans isolates had a high susceptibility to itraconazole (88.33%). Five percent (5%) of the isolates were susceptible in dose dependent (S-DD) with Minimum Inhibitory Concentrations (MICs) of 0.25 - 0.5 µg/ml while 11.67% of C. albicans isolates were resistant (MICs ≥ 1 µg/ml). Itraconazole resistance was highest among C. glabrata isolates (50%) while 32.14% were S-DD (MICs 0.25 - 0.5 µg/ml). Only 17.85% of the C. glabrata isolates were susceptible (MICs of ≤ 0.125 µg/ml). All isolates of Candida isolates were susceptible to itraconazole and clotrimazole except C. krusei which was 100% resistant to clotrimazole. All Candida species isolates had low susceptibility to topical nystatin except Candida parapsilosis that was 100% susceptible. Data also showed an emerging resistance of Candida krusei to most of the drugs used except itraconazole. The results of this study support the continued use of these antifungal drugs for the treatment of vaginal candidiasis in the pregnant women except topical nystatin.en_US
dc.identifier.citationNelson, M., Wanjiru, W., & Margaret, M. (2013). Identification and susceptibility profile of vaginal Candida species to antifungal agents among pregnant women attending the antenatal clinic of Thika District Hospital, Kenya. Open Journal of Medical Microbiology, 2013.en_US
dc.identifier.issnPrint: 2165-3372
dc.identifier.issnOnline: 2165-3380
dc.identifier.urihttps://www.scirp.org/pdf/OJMM_2013122017121204.pdf
dc.identifier.urihttp://ir-library.ku.ac.ke/handle/123456789/22501
dc.language.isoenen_US
dc.publisherScientific Research Publishingen_US
dc.titleIdentification and Susceptibility Profile of Vaginal Candida Species to Antifungal Agents among Pregnant Women Attending the Antenatal Clinic of Thika District Hospital, Kenyaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Identification and Susceptibility Profile of Vaginal Candida Species to Antifungal.pdf
Size:
297.11 KB
Format:
Adobe Portable Document Format
Description:
Full text article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
RP-Deparment of Medical Laboratory Sciences